Targeted alpha therapy for cancer

Physics in Medicine and Biology

Volumn 49, Issue 16, 2004, Pages 3703-3712

  Allen, Barry J ^a,b   Raja, Chand ^a   Rizvi, Syed ^a   Li, Yong ^a   Tsui, Wendy ^a   Zhang, David ^a   Song, Emma ^a,b   Qu, Chang Fa ^a,b   Kearsley, John ^a,b   Graham, Peter ^a   Thompson, John ^c  

^a St George Cancer Care Centre   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODIES; ONCOLOGY; PATIENT MONITORING; TOXICITY; TUMORS;

MELANOMA; TARGETED ALPHA THERAPY (TAT);

RADIOTHERAPY;

BISMUTH 213; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 2; RADIOISOTOPE;

ADVANCED CANCER; ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA RADIATION; BIOEQUIVALENCE; BREAST CANCER; CANCER CELL; CANCER CONTROL; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CHELATION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SPECIFICITY; DRUG TOLERABILITY; ELUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KINEMATICS; LEUKEMIA; LEUKEMIA CELL; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RADIOACTIVITY; SINGLE DRUG DOSE; SUBCUTANEOUS TISSUE TUMOR; TARGETED ALPHA THERAPY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR XENOGRAFT;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BISMUTH; CELL LINE, TUMOR; CHELATING AGENTS; CLINICAL TRIALS; FEMALE; FLOW CYTOMETRY; HUMANS; KINETICS; MALE; MELANOMA; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TIME FACTORS;

EID: 4444366941     PISSN: 00319155     EISSN: None     Source Type: Journal    
DOI: 10.1088/0031-9155/49/16/016     Document Type: Article

References (26)

1. Adams G P, Shatter C C, Chappell L L, Wu C, Horak E M, Simmons H H, Litwin S, Marks J D, Weiner L M and Brechbiel M W 2000 Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumours by a single-chain Fv and diabody molecules Nucl. Med. Biol. 27 339-46
2. Allen B J 1999 Targeted alpha therapy: evidence for efficacy of alpha-immunoconjugates in the management of micrometastatic cancer Australas Radiol 43 480-6
3. Allen B J, Rizvi S M A and Tian Z 2001a Preclinical targeted alpha therapy for subcutaneous melanoma Melanoma Res. 11 175-82
4. Allen B J, Rizvi S M A, Li Y, Tian Z and Ranson M 2001b In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers Crit. Rev. Oncol. Hematol. 3 139-46
5. 213Bi-labeled-PAI2 Br. J. Cancer 88 944-50
6. Emami B et al 1991 Tolerance of normal tissue to therapeutic irradiation Int.J. Rad. Oncol. Biol. Phys. 21 109-22
7. Gavrieli Y, Sherman Y and Ben-Sasoon S A 1992 Indentification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation J. Cell. Biol. 119 493-501
8. Jurcic J G et al 2002 Targeted α particle immunotherapy for myeloid leukemia Blood 100 1233-9
9. 213Bi Br. J. Cancer 80 175-84
10. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in xenograft animal model Br. J. Cancer 86 1197-203
11. Li Y, Tian Z, Rizvi S M A, Bander N H and Allen B J 2002a In vitro and preclinical studies of targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen Prostate Cancer Prostatic Disease 5 36-46
12. Li Y, Madigan M C, Lai K, Conway R M, Billson F A, Crouch R and Allen B J 2003 Human uveal melanoma expresses NG2 immunoreactivity Br. J. Ophthalmol. 87 629-32
13. 213Bi-herceptin α -conjugate Cancer Lett. 205 161-71
14. 213Bi-conjugates Int. J. Rad. Oncol. Biol. Phys. at press
15. McDevitt M R, Sgouros G, Finn R D, Humm J L, Jurcic J G, Larson S M and Schemberg D A 1998 Radioimmunotherapy with alpha-emitting nuclides Eur. J. Nucl. Med. 25 1341-51
16. 213Bi-J591) for radioimmunotherapy of prostate cancer Cancer Res. 60 6095-100
17. Mettler F A and Upton A C 1995 Medical Effects ofIonizing Radiation 2nd edn (Philadelphia, PA: Saunders)
18. Mosmann T 1983 Rapid colometric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 55-63
19. 213Bi labelled PAI2 for control of micrometastatic pancreatic cancer Preprint
20. 213Bi-C595 radioimmunoconjugate Preprint
21. Ranson M, Tian Z, Andronicos N M, Rizvi S M A and Allen B J 2002 In vitro cytotoxicity study of human breast cancer cells using Bi-213 labeled PAI2 Breast Cancer Res. Treat. 71 149-59
22. 131I-lable antitenascin monoclonal antibody 81C6 administered into surgically created researtion cavities of patients with newly diagnosed malignant gliomas J. Clin. Onc. 20 1389-97
23. Rizvi S M, Sarkar S, Goozee G and Allen B J 2000 Radioimmunoconjugates for Targeted Alpha Therapy of Malignant Melanoma Melanoma Res. 10 281-90
24. Rizvi S M R, Allen B J, Tian Z and Sarkar S 2001 In vitro and preclinical studies of targeted alpha therapy for colorectal cancer Colorectal Disease 3 345-53
25. Rizvi S M A and Henniker A J et al 2002 In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes Leukaemia Res. 26 37-43
26. Tsui W 2001 Honours Thesis University of NSW, Australia